Top Markets
#1 Palladium Network Palladium Network +27.93%
#2 Siren Siren +24.37%
#3 Ankr Network Ankr Network +21.67%
#4 BankrCoin BankrCoin +20.82%
#5 MarsCoin MarsCoin +19.10%
#6 Hive Hive +18.36%
#7 StonkBroker StonkBroker +15.72%
#8 Status Status +13.12%
#9 Prom Prom +10.71%
#10 Provenance Blockchain Provenance Blockchain +8.75%
Coin of the day
Palladium Network Palladium Network
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Voyager Therapeutics, Inc. Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc.

VYGR
Rangering i aksjer #18071
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating... Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Aksjekurs
$3.54
Sist synkronisert: 2026-09-02
Markedsverdi
$213.59M
Endring (1 dag)
3.06%
Endring (1 år)
-3.94%
Land
US
Handel Voyager Therapeutics, Inc. (VYGR)

Kategori

Healthcare
P/E-forhold for Voyager Therapeutics, Inc. (VYGR)
P/E-forhold per 2026 TTM: 0
Ifølge Voyager Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Voyager Therapeutics, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.